Valganciclovir therapy for immune recovery uveiti complicated by macular edema

Purpoe To determine whether treatment with valganciclovir will improve viual acuity in eye with immune recovery uveiti complicated by macular edema. Deign Propective open label controlled Phae II drug tudy. Method Five patient with chronic macular edema a a reult of immune recovery uveiti were tudied. Baeline fluorecein angiogram, bet-corrected ETDR viion, and cytomegaloviru (CMV) lymphoproliferative T-cell function aay were obtained and repeated after three month of valganciclovir therapy (900 mg daily) and again three month after withdrawal of therapy. Reult Viion improved by a mean of 11 letter in the treatment phae (P = .05). Graded angiogram howed three patient had treatment reduction of macular edema. One patient had rebound increae in macular edema after the withdrawal phae. The CMV lymphoproliferative repone wa not affected by the valganciclovir. Concluion Reult ugget valganciclovir treatment may benefit viual acuity in patient with macular edema from immune recovery uveiti.